What is HC Wainwright’s Forecast for LABT FY2026 Earnings?

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT – Free Report) – HC Wainwright issued their FY2026 earnings per share (EPS) estimates for shares of Lakewood-Amedex Biotherapeutics in a research report issued on Tuesday, November 17th. HC Wainwright analyst M. Keller anticipates that the company will post earnings per share of ($1.75) for the year. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Lakewood-Amedex Biotherapeutics’ current full-year earnings is ($1.75) per share.

Other analysts have also issued reports about the company. Weiss Ratings upgraded Lakewood-Amedex Biotherapeutics from a “sell (e-)” rating to a “sell (e)” rating in a report on Friday, October 2nd. Wall Street Zen downgraded shares of Lakewood-Amedex Biotherapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, November 7th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Lakewood-Amedex Biotherapeutics has a consensus rating of “Hold”.

Read Our Latest Research Report on LABT

Lakewood-Amedex Biotherapeutics Trading Up 15.0%

Shares of NASDAQ LABT opened at $0.24 on Friday. Lakewood-Amedex Biotherapeutics has a 52 week low of $0.17 and a 52 week high of $98.20. The company’s 50-day moving average price is $0.80 and its 200 day moving average price is $5.13. The stock has a market cap of $580,413.00 and a price-to-earnings ratio of -0.05.

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT – Get Free Report) last posted its earnings results on Monday, November 16th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.10).

About Lakewood-Amedex Biotherapeutics

(Get Free Report)

Lakewood-Amedex Biotherapeutics is a biotechnology company focused on developing treatments for bacterial infections, including infections caused by drug-resistant pathogens. Its research centers on bisphosphocins, a class of investigational antimicrobial compounds. The company’s activities are primarily research and development; its investigational compounds should not be confused with approved medicines or commercially available products. Publicly available information about its specific product pipeline, operating geographies and leadership is limited.

Featured Articles

Receive News & Ratings for Lakewood-Amedex Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakewood-Amedex Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.